Trials / Withdrawn
WithdrawnNCT03764137
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [89Zr]Panitumumab PET-MRI | All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging. |
Timeline
- Start date
- 2019-03-14
- Primary completion
- 2025-01-01
- Completion
- 2026-01-01
- First posted
- 2018-12-04
- Last updated
- 2025-01-31
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03764137. Inclusion in this directory is not an endorsement.